Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 17, 2020

Feinstein Institutes reports positive data of lupus nephritis drug

The Feinstein Institutes for Medical Research and Northwell Health’s Division of Rheumatology in the US have announced improved renal response with belimumab in a Phase III clinical trial for lupus nephritis.

The Feinstein Institutes for Medical Research and Northwell Health’s Division of Rheumatology in the US have announced improved renal response with belimumab in a Phase III clinical trial for lupus nephritis.

Lupus nephritis is termed as a disorder characterised by inflammation in the kidneys of systemic lupus erythematosus (SLE) patients.

According to the study data published in the New England Journal of Medicine, belimumab could become the first US Food and Drug Administration (FDA)-approved drug to treat lupus nephritis.

Named BLISS-LN trial, the study assessed the safety and efficacy of belimumab in 448 patients with biopsy-proven active lupus nephritis at 107 sites across 21 countries.

GlaxoSmithKline (GSK) funded the trial, where participants were administered intravenous belimumab or placebo at a dose of 10mg/kg along with standard therapy.

Overall, 43% of patients reached the primary objective of primary efficacy renal response at week 104.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The study showed that belimumab mitigated the risk of worsening kidney function by nearly 50% versus standard therapy alone.

Northwell Health Rheumatology division chief and study lead Richard Furie said: “This history-making clinical trial is the first successful study after decades of attempts with other lupus nephritis therapies.

“This trial will hopefully lead to the FDA’s approval to extend belimumab’s use to lupus nephritis, which represents the greatest unmet need for patients with SLE.”

In SLE patients, the immune system attacks the body’s tissues, leading to inflammation and damage to the affected organs. It can potentially affect the joints, skin, brain, lungs, kidneys and blood vessels.

About 25% to 60% of SLE patients are detected with lupus nephritis, which is related to high morbidity and mortality.

In March this year, the Feinstein Institutes for Medical Research at Northwell Health collaborated with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to study potential treatments for Covid-19.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU